Motavizumab (treatment)
Motavizumab is an anti-RSV humanized IgG1 MAb that was derived by affinity maturation of palivizumab (Synagis ®) and is 10-20 times more potent than palivizumab at neutralizing RSV in tissue culture. It is being studied for the treatment of active RSV disease. This study evaluates the effect of a single IV dose of motavizumab for the treatment of children hospitalized with RSV illness.

Anti-CD19 BiTE® (MEDI-538) *
Blinatumomab, also known as MEDI-538/MT103 is a bispecific antibody derivative (BiTE antibody) that targets CD19 positive B cells and recruits CD3 T cells to break up these B cells. It is being developed, with partner Micromet, for hematological malignancies.

Anti-IL13 MAb (CAT-354)
CAT-354 is a human MAb (IgG4) that potently and specifically neutralizes interleukin-13, a T-lymphocyte-derived cytokine that plays a key role in the development and maintenance of the human asthmatic phenotype. Therefore CAT-354 has potential in the treatment of asthma.

Anti-IL9 MAb (MEDI-528)
MEDI-528 is a fully humanized immunoglobulin (Ig) G1 MAb derived from a murine, anti-human IL-9 MAb. This program, licensed under an exclusive licensing agreement from Genaera, Inc. in 2001, is being developed for the treatment of moderate to severe asthma. The specific activity of MEDI-528 is directed at blocking the actions of IL-9, which has shown to reduce the airway inflammation and airway hyperresponsiveness seen in animal models of asthma.

Epstein-Barr Virus Vaccine
The Epstein - Barr virus (EBV) vaccine is a subunit vaccine that is a single chain transmembrane glycoprotein called gp350. The glycoprotein gp350 is the viral receptor that allows EBV to enter human cells. This vaccine is being developed through a partnership between MedImmune and GSK.

Anti-IFNα MAb (MEDI-545)
MEDI-545 (initial designation MDX-1103) is an anti-IFNα fully human monoclonal antibody for immunology indications like systemic lupus erythematosus (SLE). This program was licensed under an exclusive licensing agreement from Medarex, Inc. MEDI-545 binds to multiple interferon-alpha (IFN-α) subtypes. IFN-α subtypes are cytokines that belong to the Type I interferon family. Interferons are produced in response to various stimuli. Type I interferons are known to inhibit viral replication and contribute to immune system regulation. A substantial body of evidence suggests that Type I IFNs, including IFN-α subtypes, may also play a role in autoimmune diseases, such as systemic lupus erythematosus (SLE), myositis, and rheumatoid arthritis.

* European Trial